SGLT2 inhibitors: a new pillar of the heart failure regimen
Reviews in Cardiovascular Medicine, 2021 Initially intended as an adjunct treatment for type 2 diabetes mellitus (T2DM), SGLT2-inhibitors (SGLT2i) have transformed into an unexpected pillar of the heart failure (HF) regimen.
Travis DeSa +1 more
doaj +1 more source
Genetic Risk and Atrial Fibrillation in Patients with Heart Failure [PDF]
, 2020 Aims: To study the association between an atrial fibrillation (AF) genetic risk score with prevalent AF and all-cause mortality in patients with heart failure.
Anker, Stefan D. +22 more
core +3 more sources
Contemporary characteristics and outcomes in chagasic heart failure compared with other nonischemic and ischemic cardiomyopathy [PDF]
, 2017 Background: Chagas’ disease is an important cause of cardiomyopathy in Latin America. We aimed to compare clinical characteristics and outcomes in patients with heart failure (HF) with reduced ejection fraction caused by Chagas’ disease, with other ...
Claudio R. Gimpelewicz +17 more
core +3 more sources
Reviews in Cardiovascular Medicine, 2022 Acute decompensated heart failure (ADHF) is one of the most common causes of hospital admission for cardiovascular diseases. ADHF often affects the elderly population, is associated with high morbidity, admission rate and mortality. Pulmonary congestion (
Hui Zhang +3 more
doaj +1 more source
Prevalence of prediabetes and undiagnosed diabetes in patients with HFpEF and HFrEF and associated clinical outcomes [PDF]
, 2017 Purpose: The prevalence and consequences of prediabetic dysglycemia and undiagnosed diabetes is unknown in patients with heart failure (HF) and preserved ejection fraction (HFpEF) and has not been compared to heart failure and reduced ejection ...
Christopher B. Granger +10 more
core +3 more sources
Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme [PDF]
, 2016 Aims We investigated the association between worsening renal function (WRF) that occurs during renin–angiotensin–aldosterone system inhibition initation and outcome in heart failure (HF) patients with preserved ejection fraction (HFPEF) and compared ...
Brenner +21 more
core +1 more source
Comparative effectiveness of enalapril, lisinopril, and ramipril in the treatment of patients with chronic heart failure: a propensity score-matched cohort study [PDF]
, 2017 Background: Angiotensin converting enzyme inhibitors (ACEIs) are recommended as first-line therapy in patients with heart failure with reduced ejection fraction (HFrEF). The comparative effectiveness of different ACEIs is not known. Methods and results:
Agewall, Stefan +14 more
core +1 more source
PLoS ONE, 2023 Heart failure with reduced ejection fraction (HFrEF) is accompanied by disregulation of cardiovascular function. Heart rate variability (HRV) is commonly used to assess autonomic dysfunction in HFrEF.
Gemma Fernández-Mendoza +4 more
doaj +1 more source
Benefits of combination pharmacotherapy for HFrEF [PDF]
Nature Reviews Cardiology, 2020 In a new cross-trial analysis of patients with heart failure with reduced ejection fraction, researchers predict that a comprehensive strategy combining several pharmacological approaches reduces hospitalization and mortality compared with conventional therapy.
openaire +2 more sources
Resetting the neurohormonal balance in heart failure (HF). the relevance of the natriuretic peptide (NP) system to the clinical management of patients with HF [PDF]
, 2017 The natriuretic peptide (NP) system, which includes atrial natriuretic peptide, B-type natriuretic peptide, and C-type natriuretic peptide, has an important role in cardiovascular homeostasis, promoting a number of physiological effects including ...
Rubattu, Speranza Donatella +1 more
core +2 more sources